Patents by Inventor Joachim Gante
Joachim Gante has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6602876Abstract: Compounds of the formula I wherein R1, R2 and R3 have the meanings defined herein, and also their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporoses, oncoses, apoplexy, cardiac infarct, ischaemias, inflammations, arteriosclerosis and osteolytic disorders.Type: GrantFiled: November 2, 1995Date of Patent: August 5, 2003Assignee: Merck Patent GmbHInventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer, Matthias Wiesner, Claus Fittschen
-
Patent number: 6492384Abstract: The invention relates to novel compounds of formula (I), wherein R, R1, R2, R3, n and p have the meaning defined in claim 1. Compounds are inhibitors of clotting factor Xa and can be used for the prophylaxis and/or therapy of thrombo-embolic disorders.Type: GrantFiled: December 13, 2001Date of Patent: December 10, 2002Assignee: Merck Patent GmbHInventors: Werner Mederski, Horst Juraszyk, Hanns Wurziger, Joachim Gante, Dieter Dorsch, Hans-Peter Buchstaller, Sabine Bernotat-Danielowski, Guido Melzer, Soheila Anzali
-
Patent number: 6455529Abstract: Compounds of the formula I in which R1, R2 and R3 have the stated meanings, and their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be used for the treatment of thromboses, osteoporoses, oncoses, stroke, myocardial infarct, ischemias, inflammations, arteriosclerosis and osteolytic disorders.Type: GrantFiled: May 3, 1996Date of Patent: September 24, 2002Assignee: Merck Patent Gesellschaft mit beschraenkter HaftungInventors: Joachim Gante, Hörst Juraszyk, Peter Raddatz, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer
-
Patent number: 6380430Abstract: Novel compounds of the formula I in which X, R1, R2, R3, R4 and R5 have the meaning indicated in Patent Claim 1, are inhibitors of the coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic disorders.Type: GrantFiled: December 29, 2000Date of Patent: April 30, 2002Assignee: Merck Patent Gesellschaft mit beschraenkterHaftungInventors: Dieter Dorsch, Horst Juraszyk, Werner Mederski, Joachim Gante, Hanns Wurziger, Hans-Peter Buchstaller, Sabine Bernotat-Danielowski, Guido Melzer
-
Patent number: 6204280Abstract: Compounds of the formula I wherein R1, R2 and R3 have the meanings defined herein, and also their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporoses, oncoses, apoplexy, cardiac infarct, ischaemias, inflammations, arteriosclerosis and osteolytic disorders.Type: GrantFiled: September 30, 1998Date of Patent: March 20, 2001Assignee: Merck Patent Gesellschaft mit berschrankter HaftungInventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer, Matthias Wiesner, Claus Fittschen
-
Patent number: 6028090Abstract: Novel oxazolidinone derivatives of the formula I ##STR1## in which R.sup.1 is a phenyl radical which is unsubstituted or is monosubstituted by CN, H.sub.2 N--CH.sub.2 --, A.sub.2 N--CH.sub.2 --, H.sub.2 N--C(.dbd.NH)--, H.sub.2 N--C(.dbd.NH)--NH--, H.sub.2 N--C(.dbd.NH)--NH--CH.sub.2 --, HO--NH--C(.dbd.NH)-- or HO--NH--C(.dbd.NH)--NH--,X is O, S, SO, SO.sub.2, --NH-- or --NA--,B is ##STR2## A is alkyl having from 1 to 6 C atoms, R.sup.2 is H, A, Li, Na, K, NH.sub.4 or benzyl,R.sup.3 is H or (CH.sub.2).sub.n --COOR.sup.2,E is, in each case independently of each other, CH or N,Q is O, S or NH,m is 1, 2 or 3, andn is 0, 1, 2 or 3,and physiologically compatible salts thereof are provided, which inhibit the binding of fibrinogen to the corresponding receptor and can be used for treating thrombosis, stroke, cardiac infarction, inflammations, arteriosclerosis, osteoporosis and also tumors.Type: GrantFiled: November 6, 1997Date of Patent: February 22, 2000Assignee: Merck Patent Gesellschaft mit Beschrankter HaftungInventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Guido Melzer, Sabine Bernotat-Danielowski
-
Patent number: 5908843Abstract: Novel piperazine derivatives of formula I:Y--(C.sub.m H.sub.2m --CHR.sup.1).sub.n --CO--(NH--CHR.sup.2 --CO).sub.r -- Zwherein ##STR1## R.sup.1, R.sup.2 and R.sup.7 are each, independently, --C.sub.t H.sub.2t --R.sup.9, benzyl, hydroxybenzyl, imidazolylmethyl or indolylmethyl;R.sup.3 is H or H.sub.2 N--C(.dbd.NH)--;R.sup.4 and R.sup.6 are each, independently, (H,H) or .dbd.O;R.sup.5 is H, H.sub.2 N--C(.dbd.NH)-- or H.sub.2 N--C(.dbd.NH)--NH;R.sup.8 is OH, OA or NHOH;R.sup.9 is H, OH, NH.sub.2, SH, SA, COOH, CONH.sub.2 or NH--C(.dbd.NH)--NH.sub.2 ;A is in each case, independently, alkyl having 1-4 C atoms;m and t are each, independently, 0, 1, 2, 3 or 4;n and r are each, independently, 0 or 1; andp is 0, 1 or 2,inhibit the binding of fibrinogen to the fibrinogen receptor and can be used for the treatment of thrombosis, apoplexy, cardiac infarctus, inflammation, arteriosclerosis and tumors.Type: GrantFiled: January 31, 1994Date of Patent: June 1, 1999Assignee: Merck Patent Gesellschaft mit Beschrankter HaftungInventors: Joachim Gante, Peter Raddatz, Horst Juraszyk, Sabine Bernotat-Danielowski, Guido Melzer
-
Patent number: 5776937Abstract: Compounds of the formula I ##STR1## wherein R.sup.1 and Y have the meanings indicated, and also their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporoses, oncoses, apoplexy, cardiac infarct, inflammations, arteriosclerosis and osteolytic disorders.Type: GrantFiled: November 7, 1995Date of Patent: July 7, 1998Assignee: Merck Patent Gesellschaft mit Beschrankter HaftungInventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer
-
Patent number: 5723480Abstract: Novel oxazolidinone derivatives of the formula I ##STR1## in which R.sup.1 is a phenyl radical which is unsubstituted or is monosubstituted by CN, H.sub.2 N--CH.sub.2 --, A.sub.2 N--CH.sub.2 --, H.sub.2 N--C(.dbd.NH)--, H.sub.2 N--C(.dbd.NH)--NH--, H.sub.2 N--C(.dbd.NH)--NH--CH.sub.2 --, HO--NH--C(.dbd.NH)-- or HO--NH--C(.dbd.NH)--NH--,X is O, S, SO, SO.sub.2, --NH-- or --NA--,B is ##STR2## A is alkyl having from 1 to 6 C atoms, R.sup.2 is H, A, Li, Na, K, NH.sub.4 or benzyl,R.sup.3 is H or (CH.sub.2).sub.n --COOR.sup.2,E is, in each case independently of each other, CH or N,Q is O, S or NH,m is 1, 2 or 3, andn is 0, 1, 2 or 3,and physiologically compatible salts thereof are provided, which inhibit the binding of fibrinogen to the corresponding receptor and can be used for treating thrombosis, stroke, cardiac infarction, inflammations, arteriosclerosis, osteoporosis and also tumors.Type: GrantFiled: May 29, 1996Date of Patent: March 3, 1998Assignee: Merck Patent Gesellschaft Mit Beschrankter HaftungInventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Guido Melzer, Sabine Bernotat-Danielowski
-
Patent number: 5627197Abstract: Compounds of the formula I ##STR1## wherein R.sup.1 and Y have the meanings indicated herein, and also their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporoses, oncoses, apoplexy, cardiac infarct, inflammations, arteriosclerosis and osteolytic disorders.Type: GrantFiled: February 14, 1996Date of Patent: May 6, 1997Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer
-
Patent number: 5614531Abstract: Compounds of the formula I ##STR1## and the corresponding 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives, their physiologically acceptable salts and/or solvates, inhibit the binding of fibrinogen to the corresponding receptor and can be used for the treatment of thromboses, osteoporosis, oncoses, stroke, myocardial infarct, inflammations, arteriosclerosis and osteolytic disorders.Type: GrantFiled: February 17, 1995Date of Patent: March 25, 1997Assignee: Merck Patent Gesellschaft Mit Beschrankter HaftungInventors: Horst Juraszyk, Joachim Gante, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer
-
Patent number: 5614535Abstract: Compounds of the formula I ##STR1## in which R.sup.1 and X have the meanings herein defined, their physiologically unobjectionable salts and/or solvates inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporosis, tumoral diseases, apoplexy, cardiac infarction, inflammations, arteriosclerosis and osteolytic disorders.Type: GrantFiled: August 18, 1995Date of Patent: March 25, 1997Assignee: Merck Patent Gesellschaft Mit Beschrankter HaftungInventors: Horst Juraszyk, Joachim Gante, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer
-
Patent number: 5561148Abstract: Novel oxazolidinone derivatives of the formula I ##STR1## in which R.sup.1 is a phenyl radical which is unsubstituted or is monosubstituted by CN, H.sub.2 N--CH.sub.2 --, A.sub.2 N--CH.sub.2 --, H.sub.2 N--C(.dbd.NH)--, H.sub.2 N--C(.dbd.NH)--NH--, H.sub.2 N--C(.dbd.NH)--NH--CH.sub.2 --, HO--NH--C(.dbd.NH)-- or HO--NH--C(.dbd.NH)--NH--,X is O, S, SO, SO.sub.2, --NH-- or --NA--,B is ##STR2## or ##STR3## A is alkyl having from 1 to 6 C atoms,R.sup.2 is H, A, Li, Na, K, NH.sub.4 or benzyl,R.sup.3 is H or (CH.sub.2).sub.n --COOR.sup.2,E is, in each case independently of each other, CH or N,Q is O, S or NH,m is 1, 2 or 3, andn is 0, 1, 2 or 3,and physiologically compatible salts thereof are provided, which inhibit the binding of fibrinogen to the corresponding receptor and can be used for treating thrombosis, stroke, cardiac infarction, inflammations, arteriosclerosis, osteoporosis and also tumors.Type: GrantFiled: September 22, 1994Date of Patent: October 1, 1996Assignee: Merck Patent Gesellschaft Mit Beshrankter HaftungInventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Guido Melzer, Sabine Bernotat-Danielowski
-
Patent number: 5532255Abstract: Compounds of the formula ##STR1## in which R.sup.1, X and Y have the meanings defined herein, and their salts, inhibit the binding of fibrinogen to the fibrinogen receptor and can be used for treating thrombosis, stroke, cardiac infarction, inflammations, arteriosclerosis, osteoporosis and tumors.Type: GrantFiled: April 29, 1994Date of Patent: July 2, 1996Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Peter Raddatz, Joachim Gante, Horst Juraczyk, Hanns Wurziger, Helmut Prucher, Sabine Bernotat-Danielowski, Guido Melzer
-
Patent number: 5378691Abstract: New amino acid derivatives of the formula IR.sup.1 --C.sub.p H.sub.2p --(NH).sub.y --CO--NH--CHR.sup.2 --CO--Z--C.sub.m H.sub.2m --CO--NH--CHR.sup.3 --CR.sup.4 --(CHR.sup.5).sub.n --CO--E--Q--Y Iin which R.sup.1 to R.sup.5, p, y, Z, m, n, E, Q and Y have the meanings defined herein, and the salts thereof, inhibit the activity of human plasma renin.Type: GrantFiled: August 15, 1994Date of Patent: January 3, 1995Assignee: Merck Patent Gesellschaft Mit Beschrankter HaftungInventors: Peter Raddatz, Joachim Gante, Johannes Sombroek, Claus J. Schmitges, Klaus-Otto Minck
-
Patent number: 5215966Abstract: Novel amino acid derivatives of the formula IX--Z--NH--CHR.sup.1 --CO--NR.sup.2 --CHR.sup.3 --CR.sup.4 --(CHR.sup.5).sub.n --CO--E--W'--Ywherein X, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, E, W', Y and n have the meanings defined herein and their salts inhibit the activity of human plasma renin.Type: GrantFiled: November 27, 1987Date of Patent: June 1, 1993Assignee: Merck Patent Gesellschaft mit Beschrankter HaftungInventors: Gunter Holzemann, Peter Raddatz, Claus J. Schmitges, Klaus Otto Minck, Alfred Jonczyk, Johannes Sombroek, Joachim Gante
-
Patent number: 5215967Abstract: New amino acid derivatives of the formulaR.sup.1 --Z--NR.sup.2 --CHR.sup.3 --CR.sup.4 --(CHR.sup.5).sub.a --CO--E--Q--Ywherein R.sup.1 to R.sup.5, a, Z, E, Q and Y have the meanings defined herein, and salts thereof inhibit the activity of human plasma renin.Type: GrantFiled: November 30, 1989Date of Patent: June 1, 1993Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Joachim Gante, Peter Raddatz, Johannes Sombroek, Claus J. Schmitges, Klaus O. Minck
-
Patent number: 4829053Abstract: New aminoacid derivatives of the formula IX--Z--NR.sup.2 --CHR.sup.3 --CR.sup.4 --(CHR.sup.5).sub.n --CO--E--NR.sup.6 --(CHR.sup.7).sub.s --D Iwherein X, Z, R.sup.2, R.sup.3, R.sup.4, R.sup.5, E, R.sup.6, R.sup.7, D, n and s have the meanings defined herein and their salts, inhibit the activity of human plasma renin.Type: GrantFiled: July 31, 1987Date of Patent: May 9, 1989Assignee: Merck Patent Gesellschaft Mit Beschrankter HaftungInventors: Peter Raddatz, Joachim Gante, Claus J. Schmitges, Klaus Otto Minck, Johannes Sombroek, Gunter Holzemann
-
Patent number: 4632933Abstract: New sulfur-containing imidazole derivatives of the general formula ##STR1## in which Ar is a phenyl radical which is unsubstituted or substituted by one or two halogen atoms, Y is O or S, and Z is a 1-imidazolyl or 2-methyl-1-imidazolyl radical, and their physiologically acceptable acid addition salts, have antimycotic and antibacterial activity.Type: GrantFiled: February 24, 1984Date of Patent: December 30, 1986Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Joachim Gante, Helmut Prucher, Helmut Wahlig, Volkmar Rudolph
-
Patent number: 4289774Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is 4-biphenylyl, 4-phenoxyphenyl or 4-biphenylyl or 4-phenoxyphenyl substituted in the 4'-position by F, Cl, Br or I; R.sup.2 is H, C.sub.1-4 -alkyl, hydroxy-C.sub.1-4 -alkyl or pyridyl; R.sup.3 and R.sup.6 are each H or alkyl of 1-4 carbon atoms, or together are--(CH.sub.2).sub.4 --; and R.sup.4 and R.sup.5 are each H or together are a C--C bond; at least one of the radicals R.sup.2, R.sup.3 and R.sup.6 being other than hydrogen, possess valuable pharmacological properties, e.g., lower lipid levels and are anti-thrombotic.Type: GrantFiled: October 19, 1979Date of Patent: September 15, 1981Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Erich Schacht, Hans-Adolf Kurmeier, Joachim Gante, Reinhard Lissner, Guido Melzer, Dieter Orth